Jazz Pharmaceuticals (JAZZ) Shares Sold by Alpine Woods Capital Investors LLC

Alpine Woods Capital Investors LLC cut its holdings in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,150 shares of the specialty pharmaceutical company’s stock after selling 350 shares during the quarter. Alpine Woods Capital Investors LLC’s holdings in Jazz Pharmaceuticals were worth $3,495,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of JAZZ. Gateway Investment Advisers LLC lifted its holdings in shares of Jazz Pharmaceuticals by 70.0% during the fourth quarter. Gateway Investment Advisers LLC now owns 54,024 shares of the specialty pharmaceutical company’s stock worth $7,274,000 after buying an additional 22,253 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 5.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 206,950 shares of the specialty pharmaceutical company’s stock worth $27,866,000 after buying an additional 9,856 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 36,172.9% during the fourth quarter. Acadian Asset Management LLC now owns 17,411 shares of the specialty pharmaceutical company’s stock worth $2,343,000 after buying an additional 17,363 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Jazz Pharmaceuticals by 70.5% during the fourth quarter. Rice Hall James & Associates LLC now owns 31,467 shares of the specialty pharmaceutical company’s stock worth $4,237,000 after buying an additional 13,008 shares during the last quarter. Finally, APG Asset Management N.V. lifted its holdings in shares of Jazz Pharmaceuticals by 15.9% during the fourth quarter. APG Asset Management N.V. now owns 411,754 shares of the specialty pharmaceutical company’s stock worth $46,171,000 after buying an additional 56,495 shares during the last quarter. Institutional investors own 90.62% of the company’s stock.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 877 shares of the company’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $139.62, for a total value of $122,446.74. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $150.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 267,468 shares in the company, valued at $40,120,200. The disclosure for this sale can be found here. Insiders sold 20,837 shares of company stock worth $3,200,686 over the last quarter. Company insiders own 4.30% of the company’s stock.



A number of research analysts have recently commented on the company. BidaskClub upgraded Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 14th. Wells Fargo set a $182.00 price target on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Tuesday. ValuEngine upgraded Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 11th. B. Riley upped their price target on Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a report on Thursday, May 10th. Finally, HC Wainwright set a $160.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, May 9th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $181.60.

Shares of NASDAQ:JAZZ opened at $167.51 on Friday. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $168.48. The firm has a market capitalization of $9.67 billion, a price-to-earnings ratio of 17.52, a P/E/G ratio of 0.83 and a beta of 0.97. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The company had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. research analysts predict that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply